The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active.

The present invention relates to a Fab fragment based switchable antibody system for generating site-specific antibody conjugates. Methods are described for the attachment of molecules to specific sites the Fab fragment and for the attachment of the Fab fragment to a target molecule (e.g., an antibody) directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.) The attachment is via binding of the Fab fragment to an epitope linked to the target molecule.

The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

The present invention relates to compositions and methods for the in vitro diagnosis of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.